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gories: Prospective, Retrospective, Modeling, Quality of
Life or Other. A total of 41 retrospective posters were
identiﬁed through this process, and all were evaluated
using a slightly modiﬁed ISPOR retrospective checklist (4
criteria were separated into components, yielding a total
of 14 points). This checklist helps evaluate the appropri-
ateness of the database, the study design, and the data
analysis procedures used. Posters were evaluated by three
reviewers to assess compliance with the criteria.
RESULTS: The median score was 7 points (out of 14 cri-
teria). The highest score was 11 points and the lowest
score was 5 points. More than three-fourths of the posters
did not conﬁrm the validity of their data (criterion 2),
inclusion/exclusion criteria (criterion 4b), sensitivity
analysis for controversial variables (criterion 5b), and 
the possibility of alternative explanations (criterion 10b).
More than half of the posters additionally failed to
acknowledge the study design limitations (criterion 3b),
describe the method and/or rationale for costing (crite-
rion 6), and control for confounding variables (criterion
7). CONCLUSION: Most of the posters in this conve-
nience sample ranked at the midpoint of the expanded
ISPOR checklist. Researchers should pay close attention
to the ISPOR checklist when preparing their poster pre-
sentations to assure consistently good research practices.
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OBJECTIVE: To evaluate whether the modeling posters
presented at the 2002 ISPOR Seventh Annual Interna-
tional Meeting met the standard of good research prac-
tice criteria established by British Medical Journal (BMJ)
and ISPOR. METHODS: Posters presented at the meeting
were collected onsite or from the ISPOR website. Of the
total 337 posters presented, 133 posters (39%) were eval-
uated. Of the 133 posters collected, 26 were classiﬁed 
as modeling. Nine (9) modeling posters were excluded
because they focused exclusively on the denominator or
numerator. The remaining 17 posters were evaluated in 3
major sections: a) study design (7 items for BMJ; 3 for
ISPOR); b) data validity (14 items for BMJ; 13 for
ISPOR); c) analysis and interpretation (14 items for BMJ;
23 for ISPOR). RESULTS: More than half of the posters
satisﬁed 75% or more of the ISPOR and BMJ criteria for
study design, and only 5 failed to satisfy at least 50% of
the study design criteria. Only six posters satisﬁed 50%
or more of the BMJ data validity criteria, and none of the
posters satisﬁed 50% or more of the ISPOR data validity
criteria. More than half of the posters satisﬁed 50% or
more of the BMJ and ISPOR criteria for analysis and
interpretation. Posters were slightly more likely to satisfy
the BMJ, rather than ISPOR criteria for data validity.
Overall, the 17 posters met 51% (18/35) of the BMJ cri-
teria and 46% (18/39) of the ISPOR criteria. CONCLU-
SIONS: The number of posters reviewed and the number
of evaluators limit this study. Reviewed posters revealed
satisfactory performance in the study design elements of
the ISPOR and BMJ guidelines, but could be improved 
in data validity and analysis. Generally, the posters per-
formed better when rated using the BMJ rather than the
ISPOR guideline.
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Pharmacoepidemiology is deﬁned as the application of
epidemiological reasoning methods and knowledge to the
study of the uses and effects (beneﬁcial and adverse) of
drugs in human populations. OBJECTIVES: The purpose
of this paper is to review the emerging role of pharma-
coepidemiology in outcomes research. METHODS: This
review has been based on a systematic literature search
using Medline (PubMed), including the abstracts of the
International Conference of Pharmacoepidemiolgy since
1990, and a review of core texts recommended by the
International Society for Pharmacoepidemiology (ISPE).
RESULTS: Three core functions were highlighted by
review of the literature. The major role was found to be
in the ﬁeld of pharmacovigilance and its function in phase
IV clinical trials or postmarketing surveillance. This was
reﬂected by the predominance of pharmacovigilance
abstracts accepted by the ISPE—90% (201/223) of
abstracts in 1990 and 72% (222/309) in 2001. Pharma-
covigilance, the process of identifying and responding to
drug safety issues during phase IV of drug development,
is a key requirement of many drug regulatory authorities,
including the FDA. Pharmacoepidemiology was also
found to play a role in drug utilisation review studies and
decision analytic modeling, although its use was found 
to be less substantial, constituting the balance of the
accepted abstracts. CONCLUSION: Although pharma-
coepidemiolgy has mainly been used in the ﬁeld of phar-
macovigilance, its use in decision analysis and drug
utilisation review was found to be on the increase.
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OBJECTIVES: Current data support the use of low mol-
ecular weight heparin (LMWH) in lieu of unfractionated
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heparin (UFH) in many patients to achieve greater clini-
cal efﬁcacy and pharmacoeconomic efﬁciency. Most hos-
pitals have not achieved clinically effective use of LMWH
and UFH in the treatment and prevention of thrombotic
disorders. The Clinical Effectiveness Initiative (CEI) was
designed to help hospitals achieve better data assessment
to measure patient outcomes, reduce medical errors,
reduce risk, and reach towards optimal ﬁnancial perfor-
mance in these patient groups. METHODS: CEI begins
with analysis of data available from the UB-92 and phar-
macy or cost-accounting systems. The actuarial analysis
provides a risk-adjusted comparison of patient cohorts
receiving antithrombotics (LMWH or UFH). Results are
reported to the institution in a format suitable for use
with performance improvement activities and physicians.
The total cost for each cohort is broken down into drug
acquisition costs and costs associated with laboratory
tests, level of care, supplies and length of stay. RESULTS:
Results completed from two hospitals in 87 DRGs that
had at least 10 discharges in each drug category (5374
LMWH, 9380 UFH) showed a case mix adjusted average
savings of $698 per discharge. The study to-date has
showed that the use of LMWH reduced overall cost in
many high-use categories, despite the higher drug acqui-
sition cost. Those included DVT, Hip and Knee replace-
ment cases. Findings also demonstrated an opportunity
for substantial savings with greater selective use of
LMWH in several cohorts that will shared in chart form.
The data analysis and structured interviews with hospital
leadership presented valuable insights into how best to
facilitate changes in practice patterns that can be contin-
ually measured. CONCLUSIONS: We conclude that the
data assessment and efﬁciency modeling capabilities of
CEI are powerful tools to help hospitals achieve clinical
effectiveness, especially when integrated into a hospital’s
performance improvement program.
PHARMACOECONOMIC & OUTCOMES
RESEARCH METHODOLOGY STUDIES—
Economic Studies
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OBJECTIVES: The Japan Economic Evaluation Database
(JEED) project aims for critical appraisal of health eco-
nomic evaluation studies in Japan and build a database
with structured abstracts in collaboration with NHS-
EED. With careful preparation in 2001, we performed
handsearching of all the scientiﬁc articles and reports in
the health economic ﬁelds in Japan in 2002. We analyzed
current status of economic evaluation studies and
methodological issues. METHODS: Since January 2002,
we started to hand-search all articles and reports pub-
lished in Japanese journals. Key words for handsearching
were types of economic evaluations such as cost-
effectiveness analysis or cost-utility analysis and method-
ological terms such as utility score, willingness to pay,
QOL measurement and costing. We also adopted words
for study areas such as health economic evaluations and
pharmacoeconomics. We classiﬁed the articles into some
categories and picked up methodological issues in Japan.
RESULTS: Up to the end of September 2002, we identi-
ﬁed 223 articles and reports related to health economic
evaluations that appeared in a total of 4881 journals.
Most of the articles were general remarks or proceedings.
Thirty-four articles out of 233 were classiﬁed as original
articles, only 6 of which could be identiﬁed as full eco-
nomic evaluations. Nineteen articles were on costing and
4 were on measuring effectiveness or utility. We picked
up some issues in economic evaluation studies in Japan.
Most of the studies used reimbursement fee though there
were some studies for actual costing. Because QOL data
for health status were limited in Japanese population,
many studies adopted data from foreign countries. There
were some articles which did not use terms for economic
evaluation studies correctly. CONCLUSIONS: To
promote good economic evaluation studies in Japan, sys-
tematic critical appraisals and dissemination of informa-
tion of good studies are needed. We may have to consider
methodological guidelines or recommendations for good
economic evaluation studies.
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OBJECTIVES: Guidelines for conducting cost-utility
analyses (CUAs) contain inconsistent recommendations
for selecting cost, quality of life, and discount rate para-
meters. Sensitivity analyses can indicate whether adher-
ing to different guidelines results in different policy
recommendations. The purpose of this study is to inves-
tigate the use of sensitivity analyses to test economic 
parameters in the cost-utility literature. METHODS: Rec-
ommendations from published guidelines are summa-
rized. CUAs of pharmaceutical therapies identiﬁed in a
prior study (N = 71 articles) were reviewed and further
audited. We identiﬁed threshold CU ratios (N = 36) and
base cases for which sensitivity analyses were reported (N
= 123). For each base case, up to 2 sensitivity analyses
for cost (N = 97), quality of life (N = 136), and discount
rate (N = 127) were examined. RESULTS: There are sub-
stantial disagreements among the guidelines regarding
economic parameters. The most frequently mentioned
threshold CU ratios were $20,000/QALY, $50,000/
